St. Jude Medical Announces Launch of Ellipse ICD with Physician-Inspired Shape in India
|This is a media release from St. Jude Medical|
Design of new ICD inspired by feedback from more than 200 physicians from around the world
Hyderabad, December 13, 2012: St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced of the launch of the Ellipse™ implantable cardioverter defibrillator (ICD) in India. Some of the first implants recently took place at the Fortis Escorts Hospital in New Delhi by Dr. Aparna Jaswal, Senior Consultant Cardiologist.
ICDs are advanced implantable cardiac devices that treat potentially lethal, abnormally fast heart rhythms (ventricular tachycardia or ventricular fibrillation) that often lead to sudden cardiac death (SCD).
The Ellipse ICD provides the benefits of advanced features and power in the industry’s smallest high-energy ICD. Its unique shape was conceptualized by more than 200 physicians during focus groups where they crafted in clay their vision of ideal device design. The physician-inspired shape is unlike any currently available, with each of the enhancements designed to increase patient comfort or make the device easier to implant. The angled header and rounded edges were designed to improve the way a cardiac lead wraps around the device once connected, which can result in a smaller pocket for the device.
“We are pleased to have the new Ellipse ICD at Fortis Escorts Hospital, as it provides a balance of energy, longevity, thinness and a smaller device footprint, which collectively makes a tremendous difference for my patients,” said Dr. Jaswal.
Within its unique design, the device contains new features in addition to the industry-leading feature set provided in St. Jude Medical’s Fortify™ ICD. These features include expanded ShockGuard™ technology for protection against inappropriate and unnecessary therapy, high energy delivery, CorVue™ congestion monitoring, and enhanced ST Monitoring to offer greater insight into ischemia-related ventricular arrhythmias.
The Ellipse ICD adds SecureSense™ RV lead noise discrimination, a new algorithm that offers a strong set of lead monitoring capabilities. The new feature can differentiate lead noise from true ventricular tachycardia (VT) or ventricular fibrillation (VF) episodes, which provides the ability to automatically withhold tachycardia therapy in the presence of lead noise. An addition which helps physicians proactively lower the risk of lead-related complications.
The updated programming in ShockGuard technology provides more accurate sensing and the device is able to better discriminate between rhythms that require defibrillation and those that do not. New algorithms and enhanced detection capabilities include the ability to better discriminate between lead noise and arrhythmias that require therapy, as well as determine which heart chamber is causing the arrhythmia. These improvements are projected to reduce inappropriate therapy by 74 percent for all rhythms, allowing for more effective therapy .
Expanded ST Segment monitoring, together with the Merlin.net™ Patient Care Network and patient alerts, provide timely information to clinics that allow for better management of arrhythmias. The Ellipse ICD also incorporates the CorVue congestion monitoring algorithm – which alerts physicians when a patient’s heart failure may be worsening, as evidenced by changes in electrical signals that can be correlated to increased congestion, or fluid retention, in the chest area.
“The launch of the physician-inspired Ellipse ICD represents the company’s ongoing efforts to incorporate physician feedback into our products,” said Kaustav Banerjee, India country manager for St. Jude Medical. “The refinements to the shape of the Ellipse device, that make it easier to implant and more comfortable for the patient over time, really demonstrate the value of this approach.”
About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and Quarterly Report on Form 10-Q for the fiscal quarter ended September 29, 2012. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Priyanka P Pandit